ArticleCancer science2015

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.

Michinori Ogura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.